BMS Wins Competition For Novel Checkpoint Inhibitors With Relatlimab Approval

 
• By Joseph Haas
New cancer discovery
Bristol gets first approval for new checkpoint immunotherapy, LAG-3 • Source: Alamy

More from New Products

More from Scrip